Shanghai Junshi Biosciences (SHJBF) News Today → Fidelity, Bezos, Goldman Bet Big on Tiny Biotech (From Behind the Markets) (Ad) Free SHJBF Stock Alerts C$1.86 0.00 (0.00%) (As of 05/8/2024 ET) Add Compare Share Share HeadlinesStock AnalysisChartHeadlinesShort InterestStock AnalysisChartHeadlinesShort Interest All Sources Trusted Sources MarketBeat.com Benzinga Bloomberg MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha The Street The Wall Street Journal Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative SourceHeadlineShanghai Junshi Biosciences Co. Ltd.wsj.com - April 26 at 5:54 PMJunshi Biosciences Announces NDA Acceptance in Hong Kong for Toripalimabfinance.yahoo.com - April 24 at 10:33 PMJunshi Biosciences Announces Toripalimab’s NDA Accepted by the Singapore Health Sciences Authorityfinance.yahoo.com - February 2 at 3:07 AMJunshi Biosciences Announces JAMA Publication of Results from NEOTORCH, a Randomized Phase 3 Trial of Perioperative Toripalimab plus Chemotherapy for Patients with Resectable Non-Small Cell Lung Cancerfinance.yahoo.com - January 18 at 12:03 AMShanghai Junshi Biosciences Co Ltd (1877)investing.com - January 11 at 12:42 AMJunshi Biosciences Announces Publication of Results from TORCHLIGHT, a Randomized Phase 3 Trial of Toripalimab for the Treatment of Metastatic or Recurrent Triple-negative Breast Cancer in Nature Medicinefinance.yahoo.com - January 10 at 12:01 AMShanghai Lujianziforbes.com - January 6 at 2:30 PMWhat to Eat in Shanghaitravel.usnews.com - January 5 at 7:49 PMInovio stock surges to seven-month highmsn.com - January 5 at 2:48 PMJunshi Biosciences Announces Approval of the Supplemental New Drug Application for Toripalimab as Perioperative Treatment for Resectable NSCLC Patientsfinance.yahoo.com - January 2 at 12:28 PMHow long will Shanghai's lockdown last?bbc.com - December 12 at 8:56 AMWeek In Review: Tang Capital Offers $465M For LianBio Plus 80% Of Any Licenses/Divestmentsseekingalpha.com - December 3 at 8:10 AMJunshi Biosciences Announces New Chemical Entity Application for Toripalimab Accepted by Australia’s TGAfinance.yahoo.com - December 1 at 11:00 PMCoherus cancer drug undercuts Merck's Keytrudamsn.com - November 28 at 3:59 PMJunshi Biosciences Announces Lancet Infectious Diseases Publication of Results from the 2nd Phase 3 Study of VV116 for Treating COVID-19finance.yahoo.com - November 22 at 10:09 PMCoherus, Shanghai Junshi Shares Gain After U.S. Approval For Nasopharyngeal Cancer Drugmsn.com - October 31 at 7:48 PMJunshi-Coherus' Loqtorzi cancer drug wins FDA approvalmsn.com - October 30 at 8:06 AMJunshi Biosciences Presents 11 Clinical Trials of Toripalimab at the ESMO Congress 2023finance.yahoo.com - October 27 at 1:51 PMJunshi Biosciences Announces Acceptance of the Supplemental New Drug Application for Toripalimab as the First-line Treatment of Extensive-stage Small Cell Lung Cancerfinance.yahoo.com - July 19 at 11:14 PMShanghai Junshi Biosciences Co Ltd Class Hmorningstar.com - July 15 at 6:41 PMJunshi Biosciences Announces Acceptance of the Supplemental New Drug Application for Toripalimabfinance.yahoo.com - July 11 at 10:44 PMShanghai OPM Biosciences Co. Ltd. Awsj.com - June 19 at 12:14 AMJunshi's toripalimab gets Chinese regulator review for expanded use in breast cancerseekingalpha.com - May 23 at 10:43 AMJunshi Biosciences Announces Acceptance of the Supplemental NDA for Toripalimab in Combination with Chemotherapy for Advanced Triple-negative Breast Cancerfinance.yahoo.com - May 23 at 10:43 AMShanghai OPM Biosciences Co Ltd (688293)investing.com - May 18 at 10:16 AMShanghai Junshi Biosciences Co Ltd (688180)investing.com - May 11 at 7:42 AMJunshi Biosciences Announces Collaboration with Dr. Reddy's to Develop and Commercialize Toripalimab in 21 Countriestmcnet.com - May 7 at 3:31 PMJunshi Biosciences Announces Primary Endpoint Met in RENOTORCH Study of Toripalimab for 1st-line Treatment of Advanced Renal Cell Carcinomamarketwatch.com - April 27 at 10:55 AMJunshi Biosciences Announces Toripalimab plus Chemotherapy Significantly Improved Event-free Survival (EFS) versus Chemotherapy as Perioperative Treatment for Resectable Stage III Non-small Cell Lung Cancer (NSCLC) in Phase 3 Neotorch Studyfinance.yahoo.com - April 20 at 9:02 PMGet Ready For Ethereum’s Shanghai Upgradeforbes.com - April 14 at 1:49 AMJunshi Biosciences Announces Phase 3 Clinical Study oftmcnet.com - April 12 at 8:57 AMJunshi Biosciences Announces Acceptance of the Supplemental New Drug Application for Toripalimab as Perioperative Treatment for Operable NSCLC Patientsfinance.yahoo.com - April 12 at 1:11 AMJunshi Biosciences Announces Phase 3 Clinical Study of Senaparib for Advanced Ovarian Cancer Maintenance Treatment Following First-line Therapy Met Primary Endpointfinance.yahoo.com - April 12 at 1:11 AMShanghai Junshi Biosciences Co., Ltd. (SHJBF)finance.yahoo.com - March 31 at 12:15 AMJunshi Biosciences Announces Ongericimab (anti-PCSK9 mAb) Met Primary Endpoints in Two Phase 3 Clinical Studiesfinance.yahoo.com - February 28 at 1:06 AMShanghai Junshi Biosciences Co Ltdreuters.com - February 17 at 7:49 AMJunshi Biosciences and Coherus Announce Positive Final Overall Survival Results of JUPITER-02, a Phase 3 Clinical Trial Evaluating Toripalimab as Treatment for Recurrent or Metastatic Nasopharyngeal Carcinomafinance.yahoo.com - February 15 at 1:06 PMJunshi Biosciences Announces Approval for Marketing of VV116 in Chinafinance.yahoo.com - January 30 at 8:42 AMJunshi Biosciences Announces Toripalimab as Perioperative Treatment for Operable NSCLC Patients Met Primary Endpoint in Phase 3 Clinical Studyfinance.yahoo.com - January 18 at 1:33 AMJunshi Biosciences Announces Acceptance of NDA for VV116 in Chinafinance.yahoo.com - January 18 at 1:33 AM Get Shanghai Junshi Biosciences News Delivered to You Automatically Sign up to receive the latest news and ratings for SHJBF and its competitors with MarketBeat's FREE daily newsletter. Email Address Elon’s New Device is About to Shock the World (Ad)Using this device you see above… Elon Musk just tested a new type of A.I. that according to Wired Magazine will usher in… “The next step in human evolution.” Click here to see the details because there’s a lot of money at stake. SHJBF Media Mentions By Week SHJBF Media SentimentLearn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. SHJBF News Sentiment▼0.000.36▲Average Medical News Sentiment SHJBF News CoverageLearn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. SHJBF Articles This Week▼00▲SHJBF Articles Average Week Get Shanghai Junshi Biosciences News Delivered to You Automatically Sign up to receive the latest news and ratings for SHJBF and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies: Algernon Pharmaceuticals News ALK-Abelló A/S News Alpha Tau Medical News Arno Therapeutics News Artelo Biosciences News Ascletis Pharma News Awakn Life Sciences News AXIM Biotechnologies News BerGenBio ASA News BriaCell Therapeutics News Headlines Tools: Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (OTCMKTS:SHJBF) was last updated on 5/8/2024 by MarketBeat.com Staff From Our PartnersThe #1 Biotech Stock to Watch in 2024 is Attacking Viruses in a Unique WaySmallcaps DailyTech GIANT’s Plans to Revolutionize Crypto…Crypto 101 MediaAI “wealth window” is closing June 25thParadigm PressCharles Payne Demystifies OptionsUnstoppable ProsperityThe AI Stock that’s Disrupting Every IndustryStockEarningsShocking: One AI startup's revenue could surge 4,735%Manward Press[URGENT] DO NOT Touch These AI Stocks!Weiss RatingsHe Is Giving Away BitcoinCrypto Swap Profits Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Shanghai Junshi Biosciences Co., Ltd. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
